Midostaurin as a Novel Drug for the Therapy of FLT3 Mutation-positive Acute Myeloid Leukaemia
10.3969/j.issn.1008-049X.2018.03.035
- VernacularTitle:治疗FLT3突变的急性髓系白血病的新药米哚妥林
- Author:
Li LIU
1
;
Yang YANG
;
Xiao JIANG
;
Lijun DING
;
Tingting XIA
;
Tingting XU
Author Information
1. 湖北医药学院附属随州医院药学部 湖北随州441300
- Keywords:
Midostaurin;
FMS-like tyrosine kinase 3;
Acute myelocytic leukemia
- From:
China Pharmacist
2018;21(3):490-492
- CountryChina
- Language:Chinese
-
Abstract:
Midostaurin is an orally administered inhibitor of multiple tyrosine kinase receptors developed by Novartis Pharmaceuti-cals. In May 2017,it was approved in the USA for the treatment of adult patients with newly diagnosed FMS-like tyrosine kinase 3 (FLT3) mutation-positive acute myeloid leukaemia (AML). Its pharmacokinetics,pharmacodynamics,clinical trials,adverse effects and drug interactions were introduced in the paper.
